Literature DB >> 21076605

Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives.

Marc L Citron1.   

Abstract

The dose intensity of adjuvant chemotherapy for breast cancer is an important predictor of clinical outcome. Dose-dense chemotherapy increases the dose intensity of the regimen by delivering standard-dose chemotherapy with shorter intervals between the treatment cycles. The rationale for dose-dense therapy stems from the Norton-Simon hypothesis: Sequential, consecutive dosing of chemotherapy using single or a combination of agents increases the dose density over alternating dosing, improving results. Supporting adjuvant studies, such as C9741, and the ensuing clinical experience indicate an improved disease-free and overall survival. Dosedense adjuvant chemotherapy improves clinical outcomes without increasing toxicity.

Entities:  

Year:  2008        PMID: 21076605      PMCID: PMC2974980          DOI: 10.1159/000148914

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  21 in total

Review 1.  The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens.

Authors:  Richard Simon; Larry Norton
Journal:  Nat Clin Pract Oncol       Date:  2006-08

2.  A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity.

Authors:  W Hryniuk; E Frei; F A Wright
Journal:  J Clin Oncol       Date:  1998-09       Impact factor: 44.544

3.  Dose-Dense Therapy.

Authors:  Michael Untch; Jonas Bergh; Mark Citron; Clifford A Hudis; Jens Huober; Volker Möbus; Günter Steger
Journal:  Breast Care (Basel)       Date:  2008-04-28       Impact factor: 2.860

4.  Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma.

Authors:  C Mayers; T Panzarella; I F Tannock
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

5.  Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.

Authors:  Marco Venturini; Lucia Del Mastro; Enrico Aitini; Editta Baldini; Cinzia Caroti; Antonio Contu; Franco Testore; Fulvio Brema; Paolo Pronzato; Giovanna Cavazzini; Mario Roberto Sertoli; Giuseppe Canavese; Riccardo Rosso; Paolo Bruzzi
Journal:  J Natl Cancer Inst       Date:  2005-12-07       Impact factor: 13.506

6.  A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group.

Authors:  K D Miller; A O'Neill; E A Perez; A D Seidman; G W Sledge
Journal:  Ann Oncol       Date:  2011-08-04       Impact factor: 32.976

7.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Authors:  Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

8.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.

Authors:  G Bonadonna; P Valagussa; A Moliterni; M Zambetti; C Brambilla
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

9.  Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.

Authors:  G Bonadonna; M Zambetti; P Valagussa
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

10.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Authors:  I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

View more
  21 in total

Review 1.  A way forward on the medically appropriate use of white cell growth factors.

Authors:  Thomas J Smith; Bruce E Hillner
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

Review 2.  Adipocyte and lipid metabolism in cancer drug resistance.

Authors:  Yihai Cao
Journal:  J Clin Invest       Date:  2019-07-02       Impact factor: 14.808

Review 3.  The dynamics of drug resistance: a mathematical perspective.

Authors:  Orit Lavi; Michael M Gottesman; Doron Levy
Journal:  Drug Resist Updat       Date:  2012-03-03       Impact factor: 18.500

Review 4.  Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature.

Authors:  Mattea Reinisch; Beyhan Ataseven; Sherko Kümmel
Journal:  Breast Care (Basel)       Date:  2016-02-23       Impact factor: 2.860

5.  Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine.

Authors:  Andreia de Albuquerque; Sepp Kaul; Georg Breier; Petra Krabisch; Nikos Fersis
Journal:  Breast Care (Basel)       Date:  2012-02-21       Impact factor: 2.860

6.  Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial.

Authors:  Gianluca Tomasello; Wanda Liguigli; Rossana Poli; Silvia Lazzarelli; Matteo Brighenti; Federica Negri; Alessandra Curti; Mario Martinotti; Lucio Olivetti; Massimo Rovatti; Gianvito Donati; Rodolfo Passalacqua
Journal:  Gastric Cancer       Date:  2013-11-27       Impact factor: 7.370

Review 7.  Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.

Authors:  Geralyn E Waters; Patricia Corrigan; Mandy Gatesman; Thomas J Smith
Journal:  J Oncol Pract       Date:  2012-11-06       Impact factor: 3.840

8.  Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.

Authors:  József Zsiros; Laurence Brugieres; Penelope Brock; Derek Roebuck; Rudolf Maibach; Arthur Zimmermann; Margaret Childs; Daniele Pariente; Veronique Laithier; Jean-Bernard Otte; Sophie Branchereau; Daniel Aronson; Arun Rangaswami; Milind Ronghe; Michela Casanova; Michael Sullivan; Bruce Morland; Piotr Czauderna; Giorgio Perilongo
Journal:  Lancet Oncol       Date:  2013-07-04       Impact factor: 41.316

Review 9.  Optimizing the future: how mathematical models inform treatment schedules for cancer.

Authors:  Deepti Mathur; Ethan Barnett; Howard I Scher; Joao B Xavier
Journal:  Trends Cancer       Date:  2022-03-09

10.  A Diels-Alder polymer platform for thermally enhanced drug release toward efficient local cancer chemotherapy.

Authors:  Nanami Fujisawa; Masato Takanohashi; Lili Chen; Koichiro Uto; Yoshitaka Matsumoto; Masayuki Takeuchi; Mitsuhiro Ebara
Journal:  Sci Technol Adv Mater       Date:  2021-06-24       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.